HOXD9

Across TCGA pan-cancer cohorts, HOXD9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HOXD9 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher HOXD9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HOXD9 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, LIHC, and PAAD are the cancer types where HOXD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.092	0.690	<.001	48	view →
LIHC	OS	Median	All	0.184	0.707	.004	15	view →
PAAD	DFS	Median	All	0.112	0.484	.015	12	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
SKCM	OS	Median	All	0.834	0.307	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HOXD9–STAD (OS)

Open the STAD breakdown →